Boehringer Hits Above The Belt With Zantac Purchase
This article was originally published in The Tan Sheet
Executive Summary
Boehringer Ingelheim looks to expand its therapeutic territory up the GI tract with a $509.5 mil. purchase of U.S. rights to the acid reducer Zantac (ranitidine) from Johnson & Johnson and the Pfizer Consumer Healthcare business
You may also be interested in...
Pfizer Buy Pushes Double-Digit Growth For J&J Consumer Product Sales
Johnson & Johnson's consumer products sales jumped 48.5 percent to $3.49 billion in the firm's first fiscal quarter since closing its acquisition of Pfizer Consumer Healthcare
Pfizer Buy Pushes Double-Digit Growth For J&J Consumer Product Sales
Johnson & Johnson's consumer products sales jumped 48.5 percent to $3.49 billion in the firm's first fiscal quarter since closing its acquisition of Pfizer Consumer Healthcare
Pfizer Buy Pushes Double-Digit Growth For J&J Consumer Product Sales
Johnson & Johnson's consumer products sales jumped 48.5 percent to $3.49 billion in the firm's first fiscal quarter since closing its acquisition of Pfizer Consumer Healthcare